[go: up one dir, main page]

PE20001325A1 - Combinacion de cerivastatina y fibratos - Google Patents

Combinacion de cerivastatina y fibratos

Info

Publication number
PE20001325A1
PE20001325A1 PE1999001259A PE00125999A PE20001325A1 PE 20001325 A1 PE20001325 A1 PE 20001325A1 PE 1999001259 A PE1999001259 A PE 1999001259A PE 00125999 A PE00125999 A PE 00125999A PE 20001325 A1 PE20001325 A1 PE 20001325A1
Authority
PE
Peru
Prior art keywords
cerivastatin
combination
fibrates
refers
phenofibrate
Prior art date
Application number
PE1999001259A
Other languages
English (en)
Inventor
Joachim Ippen
Ulrike Schopen
Fritz Schuckler
Reiner Ziegler
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PE20001325A1 publication Critical patent/PE20001325A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

SE REFIERE A UNA COMBINACION DE CERIVASTATINA UTILIZANDOSE 0,025 mg A 4 mg CON UN FIBRATO DE PREFERENCIA FENOFIBRATO O BEZAFIBRATO. TAMBIEN SE REFIERE A PROCEDIMIENTOS PARA LA PREPARACION. LA CERIVASTATINA ES UN INHIBIDOR DE LA 3-HIDROXI-3-METIL-GLUTARIL-COENZIMA A (HMG-COA) Y POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS Y ENFERMEDADES DEL METABOLISMO DE LIPIDOS
PE1999001259A 1998-12-18 1999-12-16 Combinacion de cerivastatina y fibratos PE20001325A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19858789A DE19858789A1 (de) 1998-12-18 1998-12-18 Kombination von Cerivastatin und Fibraten

Publications (1)

Publication Number Publication Date
PE20001325A1 true PE20001325A1 (es) 2000-12-30

Family

ID=7891784

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001259A PE20001325A1 (es) 1998-12-18 1999-12-16 Combinacion de cerivastatina y fibratos

Country Status (19)

Country Link
US (1) US6511985B1 (es)
EP (1) EP1140082A1 (es)
KR (1) KR20010093845A (es)
CN (1) CN1330544A (es)
AR (1) AR021643A1 (es)
AU (1) AU3035600A (es)
BR (1) BR9916270A (es)
CA (1) CA2355295A1 (es)
CO (1) CO5160272A1 (es)
DE (1) DE19858789A1 (es)
GT (1) GT199900214A (es)
HN (1) HN1999000208A (es)
IL (1) IL143221A0 (es)
PE (1) PE20001325A1 (es)
PL (1) PL349389A1 (es)
SV (1) SV1999000250A (es)
TR (1) TR200101722T2 (es)
WO (1) WO2000037078A1 (es)
ZA (1) ZA200103918B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6294501A (en) 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
RS50406B (sr) 2001-01-26 2009-12-31 Schering Corporation, Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
PL202778B1 (pl) * 2001-02-22 2009-07-31 Skyepharma Canada Inc Postać dawkowana kombinacji statyny i fenofibratu, sposób jej wytwarzania i zastosowanie
US20050032878A1 (en) 2001-08-07 2005-02-10 Arthur Deboeck Oral pharmaceutical composition containing a combination pparalpha and a hmg-coa reductase inhibitor
WO2003013607A1 (en) * 2001-08-07 2003-02-20 Galephar M/F ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
DE10200138A1 (de) * 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
EP1562582A1 (en) 2002-11-06 2005-08-17 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2526730A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
CA2543596A1 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
AU2006212609A1 (en) * 2005-02-10 2006-08-17 Lifecycle Pharma A/S A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an HMG-CoA reductase inhibitor
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
JP2009543773A (ja) * 2006-07-14 2009-12-10 ランバクシー ラボラトリーズ リミテッド ＨＭＧ−ＣｏＡレダクターゼ阻害剤の多形体及びその使用
CA2657394A1 (en) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Preparation containing fibrate agent and process for producing the same
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
WO2023146320A1 (ko) * 2022-01-28 2023-08-03 동광제약 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염 및 페노피브레이트를 함유하는 캡슐 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494112B1 (es) 1980-11-19 1986-01-10 Laruelle Claude
WO1988005296A2 (en) 1987-01-27 1988-07-28 Warner-Lambert Company Lpid regulating compositions
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
CA2039763A1 (en) * 1990-04-30 1991-10-31 Henry Y. Pan Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
FR2737121B1 (fr) 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
AU752673B2 (en) * 1997-07-31 2002-09-26 Abbott Laboratories Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night

Also Published As

Publication number Publication date
HN1999000208A (es) 2000-11-22
CN1330544A (zh) 2002-01-09
WO2000037078A1 (de) 2000-06-29
PL349389A1 (en) 2002-07-15
AU3035600A (en) 2000-07-12
GT199900214A (es) 2001-06-08
CA2355295A1 (en) 2000-06-29
IL143221A0 (en) 2002-04-21
US6511985B1 (en) 2003-01-28
BR9916270A (pt) 2001-09-04
CO5160272A1 (es) 2002-05-30
TR200101722T2 (tr) 2001-11-21
SV1999000250A (es) 2000-10-16
AR021643A1 (es) 2002-07-31
KR20010093845A (ko) 2001-10-29
EP1140082A1 (de) 2001-10-10
ZA200103918B (en) 2002-05-15
DE19858789A1 (de) 2000-06-21

Similar Documents

Publication Publication Date Title
PE20001325A1 (es) Combinacion de cerivastatina y fibratos
AR064895A2 (es) Composicion farmaceutica anhidra para el tratamiento de desordenes inducidos por histamina
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
MX2009003920A (es) Estatina y acidos grasos omega 3 para reducir los niveles de apo b.
ES2123177T3 (es) Preparacion de absorcion percutanea que contiene buprenorfina.
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
BR9908690A (pt) Composição farmacêutica contendo estatina e aspirina
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
EP1510221A4 (en) MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
PT777482E (pt) Composicao de combinacao para utilizacao em doencas imunologicas
BR0013935A (pt) IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
GB2431346C (en) A combination composition comprising paracetamol and ibuprofen
ATE277611T1 (de) Zusammensetzung, l-carnitin oder alkanoyl l- carnitin und langkettige alkanole enthaltend
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
EA200500958A1 (ru) Дейтерированные производные катехоламина, а также лекарственные средства, содержащие эти соединения
DE60009652D1 (de) Pharmazeutische mischung, die ein profen und weitere aktivsubstanzen enthält
EA200200704A1 (ru) Ослабленные микроорганизмы для лечения инфекции
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
AU2976095A (en) Use of selegilin in the treatment of epileptic conditions
BR0012121A (pt) Derivado de aminotetralina para terapia de doenças cardiovasculares
PT994703E (pt) Composicao compreendendo ketanserina e l-carnitina para o tratamento de sdrc
BR9800781A (pt) Processo e dispositibo para o acionamento de uma caixa de c‰mbio
ECSP003546A (es) Una nueva composicion farmaceutica

Legal Events

Date Code Title Description
FC Refusal